- The study will begin with a screening period to make sure subjects are eligible to participate in the study.
- After the screening period, subjects who are eligible for participation will each be given several different doses of COR-003, to be taken orally in tablet form.
- After an individualized dose has been selected, participants will take COR-003 for six months.
- Finally, participants will continue in the study for an additional six months at doses to be determined by the study doctor.
Additional information on the study can be found at clinicaltrials.gov throughthis link.